We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.38%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.96B
AUM Growth
+$853M
Cap. Flow
+$1.08B
Cap. Flow %
13.6%
Top 10 Hldgs %
33.59%
Holding
163
New
28
Increased
23
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$440M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$270M
3
AFIB
Acutus Medical Inc
AFIB
+$166M
4
ACET icon
Adicet Bio
ACET
+$95.1M
5
TBPH icon
Theravance Biopharma
TBPH
+$68.6M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$119M
2
CI icon
Cigna
CI
+$82.5M
3
NTRA icon
Natera
NTRA
+$64.2M
4
ALEC icon
Alector
ALEC
+$52.6M
5
GKOS icon
Glaukos
GKOS
+$46.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 0.63%
3 Technology 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
101
Larimar Therapeutics
LRMR
$389M
$13.4M 0.17%
886,560
-47,400
-5% -$600K
OTIC
102
DELISTED
Otonomy, Inc.
OTIC
$13.2M 0.17%
+3,250,000
New +$12.3M
CMPS
103
Compass Pathways
CMPS
$1.45B
$12.2M 0.15%
+350,000
New +$12.6M
GILD icon
104
Gilead Sciences
GILD
$166B
$12.1M 0.15%
192,200
– –
BLU
105
DELISTED
BELLUS Health Inc.
BLU
$11.7M 0.15%
5,137,216
– –
ANNX icon
106
Annexon
ANNX
$800M
$11.5M 0.14%
+379,947
New +$8.91M
VRCA icon
107
Verrica Pharmaceuticals
VRCA
$92.9M
$11.5M 0.14%
147,973
– –
ALBO
108
DELISTED
Albireo Pharma Inc
ALBO
$11M 0.14%
+328,385
New +$9.57M
INZY
109
DELISTED
Inozyme Pharma
INZY
$10.5M 0.13%
+400,400
New +$9.95M
NRIX icon
110
Nurix Therapeutics
NRIX
$2.45B
$10.5M 0.13%
+300,000
New +$7.56M
TECX
111
Tectonic Therapeutic
TECX
$529M
$10.3M 0.13%
66,143
– –
CLDX icon
112
Celldex Therapeutics
CLDX
$2.81B
$9.27M 0.12%
625,000
– –
EPIX
113
DELISTED
ESSA Pharma
EPIX
$8.13M 0.1%
1,177,483
-294,370
-20% -$2M
WHWK
114
Whitehawk Therapeutics
WHWK
$182M
$7.79M 0.1%
346,263
– –
XTNT icon
115
Xtant Medical Holdings
XTNT
$59.1M
$7.62M 0.1%
9,248,678
– –
TARA icon
116
Protara Therapeutics
TARA
$218M
$7.57M 0.1%
+450,000
New +$10.4M
XFOR icon
117
X4 Pharmaceuticals
XFOR
$375M
$7.36M 0.09%
36,216
– –
SBBP
118
DELISTED
Strongbridge Biopharma plc.
SBBP
$7.33M 0.09%
+3,489,369
New +$11.8M
AKUS
119
DELISTED
Akouos Inc
AKUS
$7.2M 0.09%
315,000
– –
DYN icon
120
Dyne Therapeutics
DYN
$4.2B
$7.07M 0.09%
+350,000
New +$7.68M
HCAT icon
121
Health Catalyst
HCAT
$159M
$6.57M 0.08%
179,598
– –
OM icon
122
Outset Medical
OM
$86.4M
$6.25M 0.08%
+8,333
New +$6.84M
RCKT icon
123
Rocket Pharmaceuticals
RCKT
$336M
$5.79M 0.07%
253,108
-129,292
-34% -$3.19M
OBIO icon
124
Orchestra BioMed
OBIO
$234M
$5.5M 0.07%
+500,000
New +$5.61M
APTO
125
DELISTED
Aptose Biosciences, Inc.
APTO
$5.38M 0.07%
1,995
-118
-6% -$294K
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2020 Portfolio in Review

As of Q3 2020, OrbiMed held 163 positions worth $7.96B, up 12% from $7.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed deployed $1.08B of net new capital in Q3 2020, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was Prelude Therapeutics: 15,594,877 shares worth $470M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $119M trimmed.

  • OrbiMed's largest Q3 2020 buy was Prelude Therapeutics: 15,594,877 shares worth $470M.
  • OrbiMed added most to Adicet Bio in Q3 2020, an estimated $95.1M increase.
  • OrbiMed's biggest Q3 2020 reduction was Ascendis Pharma A/S, cutting an estimated $119M.
  • OrbiMed fully exited Cigna in Q3 2020, selling an estimated $82.5M.
  • OrbiMed's ten largest holdings make up 34% of its $7.96B portfolio in Q3 2020.
  • OrbiMed opened 28 new positions and closed 20 in Q3 2020.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $7.96B.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.